University of Sussex
Browse
Clin Oncology_chemo_ 30 Jan 2019_authors finalversion.pdf (293.97 kB)

Adjuvant chemotherapy for breast cancer in older women: an analysis of retrospective English cancer registration data

Download (293.97 kB)
journal contribution
posted on 2023-06-09, 16:35 authored by S E Ward, G R Holmes, A Ring, P D Richards, J L Morgan, J W Broggio, K Collins, Malcolm ReedMalcolm Reed, L Wyld
Aims Adjuvant chemotherapy is recommended as a treatment for women with high recurrence risk early breast cancer. Older women are less likely to receive chemotherapy than younger women. This study investigated the impact of chemotherapy on breast cancer-specific survival in women aged 70 + years using English registry data. Materials and methods Cancer registration data were obtained from two English regions from 2002 to 2012 (n = 29 728). The impact of patient-level characteristics on the probability of receiving adjuvant chemotherapy was explored using logistic regression. Survival modelling was undertaken to show the effect of chemotherapy and age/health status on breast cancer-specific survival. Missing data were handled using multiple imputation. Results In total, 11 735 surgically treated early breast cancer patients were identified. Use of adjuvant chemotherapy has increased over time. Younger age at diagnosis, increased nodal involvement, tumour size and grade, oestrogen receptor-negative or human epidermal growth factor receptor 2-positive disease were all associated with increased probability of receiving chemotherapy. Chemotherapy was associated with a significant reduction in the hazard of breast cancer-specific mortality in women with high risk cancer, after adjusting for patient-level characteristics (hazard ratio 0.74, 95% confidence interval 0.67–0.81). Discussion Chemotherapy is associated with an improved breast cancer-specific survival in older women with early breast cancer at high risk of recurrence . Lower rates of chemotherapy use in older women may, therefore, contribute to inferior cancer outcomes. Decisions on potential benefits for individual patients should be made on the basis of life expectancy, treatment tolerance and patient preference.

History

Publication status

  • Published

File Version

  • Accepted version

Journal

Clinical Oncology

ISSN

0936-6555

Publisher

Elsevier

Department affiliated with

  • BSMS Publications

Full text available

  • Yes

Peer reviewed?

  • Yes

Legacy Posted Date

2019-04-26

First Open Access (FOA) Date

2020-05-20

First Compliant Deposit (FCD) Date

2019-04-26

Usage metrics

    University of Sussex (Publications)

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC